Understanding how DDX5 affects hepatitis B virus and liver cancer development
Official title: Role of DDX5 in Hepatitis B virus transcription and hepatocarcinogenesis
Funded at Purdue University · NIH-10789936 · Data updated 2026-11-12
This study is looking at a protein called DDX5 to see how it affects the immune system and gene activity in people with hepatitis B, helping us understand why some of them might develop liver cancer, with the hope of finding new ways to treat this condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project start | February 16, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $196,250 |
| NIH project number | 5R21AI170712-02 |
| Project ID | NIH-10789936 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with chronic hepatitis B infection or those at risk for HBV-related liver cancer.
✕Less likely to help
Patients without hepatitis B infection or those with liver cancer unrelated to HBV may not benefit from this research.
What this research studies
This research investigates the role of a protein called DDX5 in the context of hepatitis B virus (HBV) infection and its potential link to liver cancer. The researchers aim to understand how DDX5 influences immune responses and gene expression related to HBV, which could provide insights into why some patients develop liver cancer after infection. By analyzing liver cancer cell lines and identifying proteins that interact with DDX5, the study seeks to uncover mechanisms that could lead to new treatment strategies for HBV-related liver cancer.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients with hepatitis B and reduce the risk of developing liver cancer.
How similar studies have gone: Previous studies have shown promising results in understanding the role of immune signaling in viral infections, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Purdue University
West Lafayette, United States Active
Researchers
- Principal investigator: Kazemian, Majid — Purdue University
- Study coordinator: Kazemian, Majid
Related research
Other NIH-funded projects on the same topics.
-
HBV cure clues in people with and without HIV
This project studies how HBV-specific B and T cell responses relate to curing hepatitis B in people with and without HIV.
-
HBV cure factors in people with and without HIV
This project studies how HBV-specific immune cells behave during treatment and whether people with HIV respond differently than those without HIV.
-
HBV prevention in community pharmacies: a first step in a low-resource setting
This pilot project tests whether hepatitis B screening and vaccination can be integrated into everyday community pharmacy services to reach more people.
-
Blood markers to catch early liver cancer in Hispanic people with hepatitis B
This project will see if a blood test can find liver cancer earlier in Hispanic people who have chronic hepatitis B.
-
Early blood markers to find hepatitis B–related liver cancer in Hispanics
This project will use immune-related blood markers to find liver cancer earlier in people with chronic hepatitis B, focusing on Hispanic adults.
-
HBV safety with long-acting HIV therapy for people with HIV
A study to understand how long-acting HIV meds affect hepatitis B in people living with HIV and how to best monitor and protect them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.